SLT : Selective Laser Trabeculoplasty
A simple in-office procedure, selective laser trabeculoplasty (SLT) has been shown to lower IOP as effectively as medication, and to offer a consistent safety profile. Best of all, it is efficacious at every stage of the glaucoma treatment algorithm. On average, SLT achieves a reduction in IOP of 30% when used as a first-line option.
Also known as Selective Laser Trabeculoplasty, SLT lowers IOP as effectively as medication, has a consistent safety profile, and – best of all – is efficacious at every stage of the glaucoma treatment algorithm.
SLT is particularly well suited to patients who are known to be non-compliant with medication. It is also effective as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail. Most importantly, SLT can deliver effective IOP control without the compliance issues and side effects associated with drug therapy.
High Benefit-Risk Ratio
When you consider the risk of complications and side effects associated with SLT versus other glaucoma therapies, SLT has one of the highest benefit-to-risk ratios of all ophthalmic procedures.
A highly effective primary therapy option, especially in non-compliant patients or in patients who have difficulty taking medications, SLT can also be used to reduce the number of medications required to control IOP – and thereby free your patients from the compliance issues and side effects associated with medications.